Helix Biopharma Corp. (OTCQX: HXBPF) has completed patient enrollment, with the required 120th patient randomized to enter the trial. The patient enrollment is for Phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW).
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
The double-blind and placebo-controlled Phase II trial is currently underway at multiple centers in Germany and Sweden. Participants will self-administer active treatment or control cream to the external ano-genital region twice-daily, with a follow-up visit at 16 weeks. Only female subjects were enrolled in the trial to avoid inter-sex treatment variations.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
